Jim Cramer Says Doximity is "Still Too Expensive"

Doximity, Inc. (NYSE:DOCS) is one of the stocks Jim Cramer mentioned in his latest comments. During the lightning round, a caller mentioned that they were not sure if they should sell their position in the stock, and Cramer replied:

“No, no, it’s still too expensive, and I didn’t think the quarter was as good as you think. I was actually surprised that this stock ever got as high as it did. I want to wait on that one. I do not want you to buy it here.”

Doximity, Inc. (NYSE:DOCS) operates a digital platform that offers medical professionals tools for collaboration, career management, research updates, documentation, and virtual patient care. A caller asked for Cramer’s opinion on the stock during the May 21 episode, and Cramer remarked:

“That was a bad miss. That was a bad miss, and that’s a high-growth company that had just been building up ahead of steam, and I cannot recommend that company because that was an unfathomable miss, frankly. And I feel very badly about saying that, but I was quite surprised. I cannot get behind that.”

Since the above comment was aired, the company’s stock is up less than 1%.

While we acknowledge the potential of DOCS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.